Health
Orally administered experimental drug halts SARS-CoV-2 replication, prevents infection – News-Medical.Net
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental…
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental drug EIDD-2801 halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue.
Separate phase 2 and 3 clinical trials are ongoing to evaluate EIDD-2801 safety in humans and its effect on viral shedding in COVID-19 patients.
The number of new COVID-19 cases continues to…
-
Business22 hours agoThese 2 ASX 200 blue-chip stocks just hit new record highs
-
Business23 hours agoDoes Macquarie rate Rio Tinto shares a buy, hold or sell after its big news?
-
Noosa News23 hours agoLeague blocked trades that didn’t benefit expansion clubs claims former AFLW coach Nathan Burke
-
Noosa News22 hours agoBus driver attacker avoids time behind bars but major twist emerges